EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.

View source ↗

Summary

The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Bronchogenic Carcinoma
• Fallopian Tube Neoplasms
• Ovarian Neoplasms
• Peritoneal Neoplasms
• Renal Cell Carcinoma

Drugs mentioned

• Kyomarc (bevacizumab)

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Renal Cell;Carcinoma, Bronchogenic;Fallopian Tube Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Peritoneal Neoplasms. MAH: Amgen Europe B.V.. Decision date: 10/11/2017